Oakview Capital Management L.P. increased its holdings in Pfizer (NYSE:PFE) by 13.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 752,510 shares of the biopharmaceutical company’s stock after purchasing an additional 86,383 shares during the period. Pfizer makes up 12.1% of Oakview Capital Management L.P.’s portfolio, making the stock its biggest position. Oakview Capital Management L.P.’s holdings in Pfizer were worth $27,256,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of PFE. Investment Centers of America Inc. increased its holdings in shares of Pfizer by 2.3% during the third quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock worth $6,990,000 after buying an additional 4,472 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its holdings in shares of Pfizer by 437.9% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock worth $27,607,000 after buying an additional 629,361 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Pfizer by 3,116.6% during the fourth quarter. SG Americas Securities LLC now owns 1,186,121 shares of the biopharmaceutical company’s stock worth $42,961,000 after buying an additional 1,149,246 shares in the last quarter. Oldfield Partners LLP increased its holdings in shares of Pfizer by 33.1% during the fourth quarter. Oldfield Partners LLP now owns 109,850 shares of the biopharmaceutical company’s stock worth $3,979,000 after buying an additional 27,300 shares in the last quarter. Finally, WealthTrust Fairport LLC increased its holdings in shares of Pfizer by 5.2% during the third quarter. WealthTrust Fairport LLC now owns 64,333 shares of the biopharmaceutical company’s stock worth $2,297,000 after buying an additional 3,188 shares in the last quarter. 69.53% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer opened at $35.72 on Wednesday, Marketbeat reports. Pfizer has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a market capitalization of $212.16 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.77 and a beta of 0.89. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.45.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm had revenue of $12.91 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same period last year, the firm earned $0.69 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. equities analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, May 11th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a yield of 3.81%. Pfizer’s payout ratio is presently 51.32%.
Several analysts have recently weighed in on PFE shares. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 24th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research note on Wednesday, January 24th. SunTrust Banks reissued a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Finally, Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $40.08.
In other Pfizer news, insider Douglas M. Lankler sold 50,000 shares of the stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total value of $1,844,500.00. Following the sale, the insider now directly owns 133,057 shares in the company, valued at $4,908,472.73. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 132,312 shares of the stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 380,349 shares of company stock worth $13,829,340. Insiders own 0.06% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.